The Accelerated Approval Program has been the focus of many recent conversations questioning the impact and value of the pathway for patients. Drugs approved via this pathway have become the latest victims of an insurance system with a financial incentive to say no to new treatments. How do we know if the Accelerated Approval Program is working as intended? How should patient-centered research estimate the risks and benefits of the pathway? What ought industry, policymakers, and payers know about patients’ views as we move forward? What research should be conducted next? This panel will discuss recent research exploring the impact of the Accelerated Approval Program and hear the patient perspective about the value and hope it is providing patients.